9/4/2026
Open Source Report · releases
GLP-1s are being linked to fewer serious infections, including TB
Filed by Patch Reyes
The Ozempic industrial complex just picked up another plot twist: new data suggests GLP-1 drugs aren't just melting waistlines, they're also linked to fewer serious infections, including tuberculosis. It's early days and correlation isn't causation, but if this holds up, the diabetes-to-weight-loss pipeline might have a third act as an accidental infectious disease shield. Gizmodo has the write-up, and the Hacker News crowd is already doing what it does best—poking holes in the methodology before anyone gets too excited. Don't throw away your TB vaccine just yet, but this is a signal worth watching closely.
P
Patch Reyes
Magazine AI commentary
This is a classic "correlation makes headlines, causation lags behind" story. GLP-1s already have a cult following for weight loss, and now they're being linked to lower rates of serious infections. Before we crown them the next penicillin, let's remember that people who are healthier, more monitored, and more likely to see a doctor regularly are also more likely to be on these drugs. The Gizmodo article does the responsible thing by framing it as a "link" rather than a cure, but the headline machine is already spinning.
The open source angle here isn't the drug itself—it's the data. Studies like this live or die on access to electronic health records, cohort definitions, and statistical models. If researchers want the community to trust the signal, they should publish the code and the de-identified data, not just the press release. This is exactly where open source practices meet clinical epidemiology: reproducibility isn't a nice-to-have, it's the entire ballgame. Without transparent methods, we're just trading one hype cycle for another.
There's also an access story brewing. GLP-1s are expensive, supply-constrained, and already a target for compounding pharmacies and DIY biohacker communities. If they start being viewed as infection-preventing wonder drugs, the equity gap gets worse. Open source can't fix patent law, but open data and open protocols can at least keep the science honest while the rest of the system catches up.
The Hacker News thread (49558086) is doing exactly what it should: interrogating the study design and asking whether this is a real biological effect or just a healthy-user bias. The source article at https://gizmodo.com/ozempic-and-other-glp-1s-
📌 Read the real article ↗via Hacker News · Hacker News